United Therapeutics Opens New Houston Biotech Facility
The company expands its production capacity for clinical-grade xenokidneys and xenohearts in Texas.
Updated on Oct. 20, 2026 in Biotech
Live Poll
Do you support the use of lab-grown animal organs to address the human organ transplant shortage?
United Therapeutics has launched its third designated pathogen-free xenograft production facility in Houston. The site is designed to scale commercial production of xeno-organs for future clinical trials.
Why it matters
As the demand for organ transplants continues to exceed the supply of human donors, this expansion aims to address the global organ shortage crisis through xenotransplantation.
The new facility features a biosecure barrier environment with air filtration and hundreds of miles of water conduits, while integrating solar arrays to offset energy consumption.
The players
United Therapeutics
This biotechnology company focuses on developing novel medical therapies for life-threatening diseases, including advanced organ transplantation solutions.
Dr. Bartley P. Griffith
He is a renowned surgeon who performed the first successful human xenoheart transplant and has been a central figure in advancing interspecies transplant research.
Dr. Robert A. Montgomery
He is a leading transplant surgeon and researcher known for conducting the first xenokidney transplant as part of the EXPAND clinical trial.
The details
The facility is named in honor of Dr. Bartley P. Griffith and Dr. Robert A. Montgomery, both pioneers in the field of xenotransplantation. These specialized production centers are engineered to provide the consistent, clinical-grade organs required for advanced medical research and eventual commercial application.
Timeline
2022: Dr. Griffith conducted the first human xenoheart transplants.
2024: The first pathogen-free facility opened in Christiansburg, Virginia.
2025: Dr. Montgomery transplanted the first xenokidney in the EXPAND trial.
August 12, 2026: The second facility opened in Stewartville, Minnesota.
October 20, 2026: The third facility officially opened in Houston, Texas.
The Tech Race
This facility launch represents a critical step in industrializing xenotransplantation to move beyond early clinical trials like the EXPAND program. It positions United Therapeutics to scale production significantly, aiming to replace legacy reliance on human organ donors with bioengineered, gene-edited alternatives.
While this facility does not offer immediate treatments to the public, it establishes the groundwork for future medical accessibility to life-saving organs. Patients currently awaiting a transplant may eventually see reduced wait times once these technologies gain full regulatory approval.
The takeaway
The development of these specialized facilities highlights the rapid shift toward industrializing life-saving medical technology. As the field matures, observers should monitor updates on FDA regulatory milestones for genetically edited organ therapies.
Further reading
Learn more about the latest industry developments at Biotech.
Live Poll
Do you support the use of lab-grown animal organs to address the human organ transplant shortage?
